A detailed history of Israel Englander (Millennium Management LLC) transactions in Heron Therapeutics, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 934,388 shares of HRTX stock, worth $1.48 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
934,388
Previous 1,434,627 34.87%
Holding current value
$1.48 Million
Previous $5.02 Million 62.98%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.73 - $3.67 $865,413 - $1.84 Million
-500,239 Reduced 34.87%
934,388 $1.86 Million
Q2 2024

Aug 14, 2024

SELL
$2.32 - $3.86 $4.02 Million - $6.69 Million
-1,732,659 Reduced 54.7%
1,434,627 $5.02 Million
Q1 2024

May 15, 2024

BUY
$1.71 - $3.06 $3.3 Million - $5.91 Million
1,930,129 Added 156.01%
3,167,286 $8.77 Million
Q4 2023

Feb 14, 2024

BUY
$0.54 - $1.82 $617,416 - $2.08 Million
1,143,363 Added 1219.02%
1,237,157 $2.1 Million
Q2 2023

Aug 14, 2023

SELL
$1.11 - $2.88 $523,913 - $1.36 Million
-471,994 Reduced 83.42%
93,794 $108,000
Q1 2023

May 15, 2023

SELL
$1.51 - $3.25 $4.44 Million - $9.56 Million
-2,940,566 Reduced 83.86%
565,788 $854,000
Q4 2022

Feb 14, 2023

BUY
$2.25 - $4.67 $4.11 Million - $8.52 Million
1,825,388 Added 108.59%
3,506,354 $8.77 Million
Q3 2022

Nov 14, 2022

BUY
$2.66 - $5.37 $3.86 Million - $7.78 Million
1,449,328 Added 625.69%
1,680,966 $7.09 Million
Q2 2022

Aug 15, 2022

SELL
$2.3 - $6.29 $2.23 Million - $6.11 Million
-971,100 Reduced 80.74%
231,638 $646,000
Q1 2022

May 16, 2022

BUY
$4.63 - $9.94 $916,462 - $1.97 Million
197,940 Added 19.7%
1,202,738 $6.88 Million
Q4 2021

Feb 14, 2022

BUY
$8.35 - $12.6 $8.39 Million - $12.7 Million
1,004,798 New
1,004,798 $9.17 Million
Q3 2021

Nov 15, 2021

SELL
$10.13 - $15.0 $3.32 Million - $4.92 Million
-327,721 Closed
0 $0
Q2 2021

Aug 16, 2021

SELL
$13.27 - $18.48 $9.45 Million - $13.2 Million
-712,125 Reduced 68.48%
327,721 $5.09 Million
Q1 2021

May 17, 2021

BUY
$14.49 - $20.72 $12.2 Million - $17.4 Million
839,815 Added 419.84%
1,039,846 $16.9 Million
Q4 2020

Feb 16, 2021

SELL
$14.61 - $22.14 $61,464 - $93,142
-4,207 Reduced 2.06%
200,031 $4.23 Million
Q3 2020

Nov 16, 2020

BUY
$13.67 - $17.77 $2.79 Million - $3.63 Million
204,238 New
204,238 $3.03 Million
Q2 2020

Aug 14, 2020

SELL
$10.89 - $21.47 $5.53 Million - $10.9 Million
-507,854 Closed
0 $0
Q1 2020

May 14, 2020

SELL
$10.23 - $24.56 $2.04 Million - $4.9 Million
-199,690 Reduced 28.22%
507,854 $5.96 Million
Q4 2019

Feb 14, 2020

BUY
$17.42 - $26.61 $2.45 Million - $3.74 Million
140,613 Added 24.8%
707,544 $16.6 Million
Q3 2019

Nov 14, 2019

BUY
$16.36 - $21.39 $3.56 Million - $4.65 Million
217,302 Added 62.15%
566,931 $10.5 Million
Q2 2019

Aug 15, 2019

BUY
$16.93 - $26.22 $5.71 Million - $8.84 Million
337,296 Added 2734.91%
349,629 $6.5 Million
Q2 2019

Aug 14, 2019

SELL
$16.93 - $26.22 $885,726 - $1.37 Million
-52,317 Reduced 80.92%
12,333 $2.69 Million
Q1 2019

May 14, 2019

BUY
$23.15 - $28.34 $1.5 Million - $1.83 Million
64,650 New
64,650 $1.58 Million
Q4 2018

Feb 14, 2019

SELL
$22.03 - $32.01 $915,016 - $1.33 Million
-41,535 Closed
0 $0
Q3 2018

Nov 14, 2018

SELL
$30.0 - $40.85 $4.13 Million - $5.63 Million
-137,829 Reduced 76.84%
41,535 $1.32 Million
Q2 2018

Aug 14, 2018

BUY
$26.4 - $42.0 $4.74 Million - $7.53 Million
179,364 New
179,364 $6.97 Million
Q1 2018

May 15, 2018

SELL
$18.43 - $28.8 $5.81 Million - $9.08 Million
-315,173 Closed
0 $0
Q4 2017

Feb 14, 2018

SELL
$14.8 - $18.85 $809,574 - $1.03 Million
-54,701 Reduced 14.79%
315,173 $5.71 Million
Q3 2017

Nov 14, 2017

BUY
$14.65 - $16.85 $5.42 Million - $6.23 Million
369,874
369,874 $5.97 Million

Others Institutions Holding HRTX

About HERON THERAPEUTICS, INC.


  • Ticker HRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 118,774,000
  • Market Cap $188M
  • Description
  • Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single a...
More about HRTX
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.